UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000023130
Receipt number R000026033
Scientific Title Lymph node metastasis detection by OSNA in colon cancer: A prospective multicenter trial in Japan
Date of disclosure of the study information 2016/07/15
Last modified on 2016/07/19 17:30:51

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Lymph node metastasis detection by OSNA in colon cancer: A prospective multicenter trial in Japan

Acronym

Lymph node metastasis detection by OSNA in colon cancer: A prospective multicenter trial in Japan

Scientific Title

Lymph node metastasis detection by OSNA in colon cancer: A prospective multicenter trial in Japan

Scientific Title:Acronym

Lymph node metastasis detection by OSNA in colon cancer: A prospective multicenter trial in Japan

Region

Japan


Condition

Condition

Colorectal cancer

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To examine the clinical stage when OSNA examination result is added to the standard pathological one.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase IV


Assessment

Primary outcomes

To seek proportion of cases which are OSNA examination positive and pathological examination negative.

Key secondary outcomes

To find out predictive factors of metastasis.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Be diagnosed with colorectal cancer including colon cancer and/or rectal cancer, clinically staged No or N1. Limited to Ra and Rs in rectal cancer.
2. Signed informed consent.

Key exclusion criteria

1. who lack the capacity to consent.
2. Who receives/received preoperative chemotherapy.
3. Who is diagnosed with Rb.
4. Active double cancer.
5. who attending physicians consider to be inappropriate due to other reasons m

Target sample size

225


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Nariaki Matsuura, M.D., Ph.D.

Organization

Osaka Medical Center for Cancer and Cardiovascular Diseases

Division name

President

Zip code


Address

3-3 Nakamichi 1-Chome, Higashinari-ku, Osaka, 537-8511 Japan

TEL

06-6972-1181

Email

nmatsuura@mc.pref.osaka.jp


Public contact

Name of contact person

1st name
Middle name
Last name Contact for Marketing

Organization

Sysmex Corporation

Division name

Life Science Product Engineering

Zip code


Address

4-4-4 Takatsukadai, Nishiku, Kobe 651-2271, Japan

TEL

078-992-7055

Homepage URL


Email

lifescience@sysmex.co.jp


Sponsor or person

Institute

Osaka Medical Center for Cancer and Cardiovascular Diseases

Institute

Department

Personal name



Funding Source

Organization

Sysmex Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大分大学/Oita University
大阪大学医学部附属病院/Osaka University
大阪府立成人病センター/Osaka Medical Center for Cancer and Cardiovascular Diseases
関西ろうさい病院/Kansai Rosai Hospital
札幌医科大学/Sapporo Medical Univeristy
市立吹田市民病院/Suita Municipal Hospital
駿河台日本大学病院/Surugadai Nihon University Hospital
東京女子医科大学/Tokyo Women’s Medical Univiersity
栃木県立がんセンター/Tochigi Cancer Center
兵庫医科大学病院/Hyogo College of Medicine
箕面市立病院/Minoh City Hospital
シスメックス株式会社/Sysmex Corporation


Other administrative information

Date of disclosure of the study information

2016 Year 07 Month 15 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

http://www.ncbi.nlm.nih.gov/pubmed/26438440

Number of participants that the trial has enrolled


Results

The concordance rate between 1 slice hematoxylin/eosin and OSNA assay was 95.7 % (1,842/1925 lymph nodes). The sensitivity and specificity of the OSNA assay were 86.2 % (125/145) and 96.5 % (1717/1780), respectively. Among 124 node-negative patients (pN0), the respective upstaging rates of pStages I, IIA, IIB, and IIC were 2.0 % (1/50), 17.7 % (11/62), 12.5 % (1/8), and 25 % (1/4). OSNA-positive patients had deeper invasion to the colonic wall and severe lymphatic invasion (P = 0.048 and P = 0.004, respectively).

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 02 Month 20 Day

Date of IRB


Anticipated trial start date

2012 Year 04 Month 01 Day

Last follow-up date

2013 Year 08 Month 31 Day

Date of closure to data entry

2014 Year 03 Month 04 Day

Date trial data considered complete

2014 Year 06 Month 16 Day

Date analysis concluded

2014 Year 07 Month 18 Day


Other

Other related information

Patient enrollment: patients from 11 institutes who met eligibility criteria of the study between the periods after IRB approval until August of 2013 were enrolled in the study.


Management information

Registered date

2016 Year 07 Month 12 Day

Last modified on

2016 Year 07 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026033


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name